Boston Scientific to Present at TD Cowen Healthcare Conference: What Investors Should Watch For
Boston Scientific Corporation (NYSE: BSX) will be participating in the TD Cowen 46th Annual Health Care Conference on March 3, 2026. CEO Mike Mahoney and Dr. Kenneth Stein, senior vice president and global chief medical officer, will be presenting and engaging in a question-and-answer session at approximately 9:10 a.m. ET. A live webcast will be available, with a replay accessible shortly after the event concludes, at https://investors.bostonscientific.com.
Recent Performance and 2026 Outlook
Boston Scientific recently announced its fourth quarter and full year 2025 results on February 4, 2026, reporting revenue of $5.29 billion for Q4 (a 15.9% year-over-year increase) and $20.1 billion for the full year (a 19.9% year-over-year increase). The company is projecting organic growth of 10%-11% for the full year 2026, building on strong momentum in areas like Electrophysiology (EP), Watchman, and cardiovascular segments.
Strategic Acquisitions and Portfolio Expansion
Boston Scientific has been actively expanding its portfolio through strategic acquisitions. In January 2026, the company announced agreements to acquire both Penumbra, Inc. To bolster its cardiovascular offerings, and Valencia Technologies Corporation to expand its urology solutions. These moves signal a commitment to addressing prevalent vascular and urological diseases.
Innovation in Neuromodulation
Boston Scientific continues to invest in innovative therapies, as demonstrated by the presentation of multiple long-term data outcomes at the 2026 North American Neuromodulation Society (NANS) Meeting in January 2026. These studies reinforce the efficacy of spinal cord stimulation (SCS) for chronic pain management.
Analyst Perspective
TD Cowen analysts have maintained a ‘Buy’ rating on Boston Scientific stock, highlighting comments from CEO Mike Mahoney. The firm views Boston Scientific as a top pick within the sector, as noted in an October 10, 2025 report.
Key Takeaways for Investors
Boston Scientific’s recent financial performance and strategic initiatives position the company for continued growth. The TD Cowen conference presentation will likely provide further insights into the company’s 2026 strategy, including details on the integration of recent acquisitions and progress in key therapeutic areas.
Did you grasp?
Boston Scientific has been a global medical technology leader for over 45 years, consistently advancing science to improve patient health.
Frequently Asked Questions
- What is the date of the TD Cowen conference presentation? The presentation will take place on Tuesday, March 3, 2026.
- Who from Boston Scientific will be presenting? Mike Mahoney, chairman and CEO, and Dr. Kenneth Stein, senior vice president and global chief medical officer, will participate.
- Where can I access the webcast? The webcast will be available at https://investors.bostonscientific.com.
- What are Boston Scientific’s key growth areas? EP, Watchman, and cardiovascular segments are driving significant growth for the company.
For media inquiries, contact Chanel Hastings at [email protected]. For investor relations inquiries, contact Lauren Tengler at [email protected].
Explore more about Boston Scientific’s innovative technologies at www.bostonscientific.com.
